AN2 Therapeutics Inc. filed SEC Form 8-K: Leadership Update
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(c) On November 4, 2024, the Board of Directors of AN2 Therapeutics, Inc. (the “Company”) appointed Joshua Eizen, the Company’s current Chief Legal Counsel, age 47, as Chief Legal Officer and Chief Operating Officer of the Company, effective immediately (the “Effective Date”). Biographical and other information required by Item 5.02(c) of Form 8-K regarding Mr. Eizen has been previously disclosed by the Company in its Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2024, which information is incorporated herein by reference.
In connection with his appointment, Mr. Eizen received an annual salary increase to $450,000, an option to purchase 63,000 shares of the Company’s common stock, and 31,500 restricted stock units. The options vest as to 1/48th of the shares on each monthly anniversary of the Effective Date, and the restricted stock unit vest as to 25% of the shares each annual anniversary of the Effective Date, in each case, subject to Mr. Eizen’s continued service with the Company.
Mr. Eizen is not and has not been involved in any related-party transactions with the Company requiring disclosure under Item 404(a) of Regulation S-K. Mr. Eizen does not have any family relationships with any other director, executive officer, or any persons nominated for such positions.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: November 5, 2024 | AN2 Therapeutics, Inc. | |||||
| By: | /s/ Lucy O. Day | |||||
| Lucy O. Day | ||||||
| Chief Financial Officer | ||||||